PL352223A1 - Modulation of excitable tissue function by peripherally administered erythropoietin - Google Patents

Modulation of excitable tissue function by peripherally administered erythropoietin

Info

Publication number
PL352223A1
PL352223A1 PL00352223A PL35222300A PL352223A1 PL 352223 A1 PL352223 A1 PL 352223A1 PL 00352223 A PL00352223 A PL 00352223A PL 35222300 A PL35222300 A PL 35222300A PL 352223 A1 PL352223 A1 PL 352223A1
Authority
PL
Poland
Prior art keywords
modulation
tissue function
excitable tissue
peripherally administered
administered erythropoietin
Prior art date
Application number
PL00352223A
Other languages
English (en)
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Original Assignee
Kenneth S Warren Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Inst filed Critical Kenneth S Warren Inst
Publication of PL352223A1 publication Critical patent/PL352223A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00352223A 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin PL352223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11
PCT/US2000/010019 WO2000061164A1 (fr) 1999-04-13 2000-04-13 Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine

Publications (1)

Publication Number Publication Date
PL352223A1 true PL352223A1 (en) 2003-08-11

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00352223A PL352223A1 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Country Status (21)

Country Link
EP (1) EP1171147A4 (fr)
JP (1) JP2003520194A (fr)
KR (2) KR101012932B1 (fr)
CN (1) CN1607957B (fr)
AU (1) AU784550B2 (fr)
BG (1) BG65353B1 (fr)
BR (1) BR0009737A (fr)
CA (1) CA2383940A1 (fr)
CR (1) CR6501A (fr)
CZ (1) CZ20013695A3 (fr)
EA (1) EA004766B1 (fr)
HU (1) HUP0201598A3 (fr)
IL (2) IL145895A0 (fr)
IS (1) IS6104A (fr)
MX (1) MXPA01010177A (fr)
NO (1) NO20014991L (fr)
NZ (4) NZ533098A (fr)
PL (1) PL352223A1 (fr)
SK (1) SK14412001A3 (fr)
TR (2) TR200103785T2 (fr)
WO (1) WO2000061164A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1295604B1 (fr) 2000-06-30 2009-09-30 Tokyo Metropolitan Institute of Gerontology Preventifs et remedes contre des maladies associees a la demyelinisation
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
NZ548578A (en) * 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
CA2476538C (fr) 2002-01-09 2012-07-17 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2004087063A2 (fr) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Utilisation de l'erythropoietine pour un retablissement a la suite d'un accident ischemique cerebral
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Ｅ1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
HUE035655T2 (en) 2005-08-05 2018-05-28 Araim Pharmaceuticals Inc Tissue protective peptides and their use
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
CN101062407A (zh) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
WO2009010107A1 (fr) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2385746C1 (ru) * 2008-07-18 2010-04-10 Владимир Алексеевич Шатров Способ лечения детского церебрального паралича
RU2432899C1 (ru) * 2010-03-23 2011-11-10 Владимир Алексеевич Тупиков Способ прогнозирования рецидива эквинусной и эквиноварусной деформаций стопы после их раннего хирургического лечения у детей с дцп
RU2519695C2 (ru) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Also Published As

Publication number Publication date
CZ20013695A3 (cs) 2002-02-13
EP1171147A1 (fr) 2002-01-16
HUP0201598A3 (en) 2002-10-28
KR101012932B1 (ko) 2011-02-08
CN1607957A (zh) 2005-04-20
TR200402194T2 (tr) 2004-10-21
WO2000061164A1 (fr) 2000-10-19
NZ560696A (en) 2010-03-26
IL145895A0 (en) 2002-07-25
AU784550B2 (en) 2006-05-04
TR200103785T2 (tr) 2002-06-21
EA200101073A1 (ru) 2002-10-31
KR20020000874A (ko) 2002-01-05
CR6501A (es) 2004-04-15
IL145895A (en) 2010-05-31
AU4348700A (en) 2000-11-14
EP1171147A4 (fr) 2003-05-14
NZ545478A (en) 2008-04-30
BR0009737A (pt) 2003-01-14
KR100883232B1 (ko) 2009-02-10
NZ514690A (en) 2004-07-30
MXPA01010177A (es) 2004-09-10
NO20014991L (no) 2001-11-15
NO20014991D0 (no) 2001-10-12
JP2003520194A (ja) 2003-07-02
NZ533098A (en) 2006-04-28
CA2383940A1 (fr) 2000-10-19
HUP0201598A2 (en) 2002-09-28
BG65353B1 (bg) 2008-03-31
CN1607957B (zh) 2012-10-10
KR20070094997A (ko) 2007-09-27
EA004766B1 (ru) 2004-08-26
SK14412001A3 (sk) 2002-03-05
BG106058A (en) 2002-12-29
IS6104A (is) 2001-10-11

Similar Documents

Publication Publication Date Title
IL145895A0 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
GB2357774B (en) Biioabsorbable cyanoacrylate tissue adhesives
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
PL351261A1 (en) Derivatives of indigoid bisindoles
AU7362400A (en) Occlusion of tubular anatomical structures by energy application
AU2492000A (en) Implantable neuro-stimulator
GB2346057B (en) Microgradient intensity modulating multi-leaf collimator r
ZA200107122B (en) Treatment of acne using lipoic acid.
AU3766700A (en) Human tumor necrosis factor receptor-like 2
AU6115400A (en) Antisense modulation of mekk5 expression
AU7876900A (en) Antisense modulation of fra-1 expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU6092900A (en) Animals comprising human hepatocellular tissue
AU6612300A (en) Ophthalmoscope attachment
AU1878201A (en) Composition for the treatment of damaged tissue
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2501200A (en) Human peptidases
AU1921100A (en) Antisense modulation of smad4 expression
TW580908U (en) Disposable diaper
AU5394300A (en) Tissue engineering
AU5605900A (en) Stabilization of n-nitrosohydroxylamines by use of absorptive material
ZA200108407B (en) Modulation of excitable tissue function by peripherally administered erythropoietin.
AU5874800A (en) Antisense modulation of ets-2 expression

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 384514

Country of ref document: PL

REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)
DISD Decisions on discontinuance of the proceedings of a derived patent or utility model

Ref document number: 388117

Country of ref document: PL